Phase I Compare OS in Post-CyberKnife Radiosurgery Tx in 1-3 VS 4 or More Brain Metastases

Trial ID or NCT#



not recruiting iconNOT RECRUITING


The investigators will learn from this study if the CyberKnife radiosurgery (CK RS) treatment of patients with 1-3 versus 4 or more brain metastases results in the same overall survivals. The importance of this new knowledge will be to determine the treatment efficacy of CK RS with 1-3 versus 4 or more brain metastases. The outcome of this trial would give data to support either the continuation or modification of the CK RS treatment of patients with brain metastases.

Official Title

A Comparison of Overall Survival Post-CyberKnife Radiosurgery Treatment of Patients With 1-3 Versus 4 or More Brain Metastases

Eligibility Criteria

Ages Eligible for Study: 21 Years to 95 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. 1. the presence of a tumor metastasis or tumor metastases to the brain as manifested by the neurological examination and visibility of the metastatic lesion(s) on MRI and CT scans 2. a Karnofsky performance status (KPS) score of greater than or equal to 60.
Exclusion Criteria:
  1. The exclusion criteria are the converse of the above, i.e. patients without a brain tumor metastasis or brain tumor metastases or a KPS of less than 60.


Steven D. Chang, MD
Steven D. Chang, MD
Neurosurgeon, Aneurysm neurosurgeon, Cerebrovascular neurosurgeon, Pituitary tumors neurosurgeon, Stereotactic neurosurgeon
Robert C. and Jeannette Powell Neurosciences Professor and, by courtesy, of Otolaryngology - Head & Neck Surgery (OHNS) and of Neurology
Iris C. Gibbs, MD, FACR, FASTRO
Iris C. Gibbs, MD, FACR, FASTRO
Radiation oncologist, Neuro-oncologist
Professor of Radiation Oncology (Radiation Therapy) and, by courtesy, of Neurosurgery

Contact us to find out if this trial is right for you.


Steven Chang